NCT05814107View on ClinicalTrials.gov

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

PHASE1RecruitingINTERVENTIONAL

Enrollment

94

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions

Type 2 DiabetesOverweight or Obesity

Interventions

DRUG

CT-996

Capsule of CT-996

DRUG

Placebo

Capsule of placebo matching CT-996.

Trial Locations (2)

3004

COMPLETED

Nucleus Network Pty Ltd., Melbourne

66260

RECRUITING

Avant Santé Research Center S.A. de C.V., San Pedro Garza García

Sponsors

Collaborators (1)

Carmot Therapeutics, Inc.

All Listed Sponsors

collaborator

Carmot Therapeutics, Inc.

INDUSTRY

collaborator

Hoffmann-La Roche

INDUSTRY

lead

Carmot Australia First Pty Ltd

INDUSTRY

NCT05814107 - Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter